Compile Data Set for Download or QSAR
Report error Found 3475 for UniProtKB: Q9BQA1
LigandPNGBDBM50462572(CHEMBL4249337)
Affinity DataIC50: 0.130nMAssay Description:Inhibition of full-length human N-terminal FLAG-tagged PRMT5/full length N-terminal His6-tagged MEP50 (unknown origin) expressed in baculovirus infec...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2021
Entry Details Article
PubMedPDB3D3D Structure (crystal)
LigandPNGBDBM50523629(CHEMBL4564327)
Affinity DataIC50: 0.160nMAssay Description:Inhibition of full-length human N-terminal FLAG-tagged PRMT5/full length N-terminal His6-tagged MEP50 (unknown origin) expressed in baculovirus infec...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2021
Entry Details Article
PubMed
LigandPNGBDBM50523642(CHEMBL4539612)
Affinity DataIC50: 0.200nMAssay Description:Inhibition of full-length human N-terminal FLAG-tagged PRMT5/full length N-terminal His6-tagged MEP50 (unknown origin) expressed in baculovirus infec...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2021
Entry Details Article
PubMed
LigandPNGBDBM533479(US11220524, Example 86-B | (Z)-7-((1R,2S,3R,4S)-4-...)
Affinity DataIC50: 0.200nMAssay Description:Compounds were solubilized, and 3-fold diluted in 100% DMSO. These diluted compounds were further diluted in the assay buffer (50 mM Tris-HCl, pH 8.5...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/14/2022
Entry Details
US Patent

LigandPNGBDBM533464(US11220524, Example 105 | (E)-7-((2R,3R,4S,5S)-5-(...)
Affinity DataIC50: 0.200nMAssay Description:Compounds were solubilized, and 3-fold diluted in 100% DMSO. These diluted compounds were further diluted in the assay buffer (50 mM Tris-HCl, pH 8.5...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/14/2022
Entry Details
US Patent

LigandPNGBDBM515298(US11098059, Example 6 | US11098059, Example 2)
Affinity DataIC50: 0.210nMAssay Description:In this assay, the potency (IC50) of each compound was determined from a twenty-point (1:2 serial dilution; top compound concentration of 100000 nM) ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2022
Entry Details
US Patent

LigandPNGBDBM515310(US11098059, Example 14)
Affinity DataIC50: 0.240nMAssay Description:In this assay, the potency (IC50) of each compound was determined from a twenty-point (1:2 serial dilution; top compound concentration of 100000 nM) ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2022
Entry Details
US Patent

LigandPNGBDBM50523646(CHEMBL4541714)
Affinity DataIC50: 0.25nMAssay Description:Inhibition of full-length human N-terminal FLAG-tagged PRMT5/full length N-terminal His6-tagged MEP50 (unknown origin) expressed in baculovirus infec...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2021
Entry Details Article
PubMed
LigandPNGBDBM515307(US11098059, Example 11 | 6'-(1-cyclopropyl-1H-1,2,...)
Affinity DataIC50: 0.290nMAssay Description:In this assay, the potency (IC50) of each compound was determined from a twenty-point (1:2 serial dilution; top compound concentration of 100000 nM) ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2022
Entry Details
US Patent

LigandPNGBDBM533440(US11220524, Example 81 | (2R,3S,4R,5R)-2-((R)-(3,4...)
Affinity DataIC50: 0.300nMAssay Description:Compounds were solubilized, and 3-fold diluted in 100% DMSO. These diluted compounds were further diluted in the assay buffer (50 mM Tris-HCl, pH 8.5...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/14/2022
Entry Details
US Patent

LigandPNGBDBM515299(US11098059, Example 7 | US11098059, Example 3)
Affinity DataIC50: 0.310nMAssay Description:In this assay, the potency (IC50) of each compound was determined from a twenty-point (1:2 serial dilution; top compound concentration of 100000 nM) ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2022
Entry Details
US Patent

LigandPNGBDBM50523655(CHEMBL4577464)
Affinity DataIC50: 0.320nMAssay Description:Inhibition of full-length human N-terminal FLAG-tagged PRMT5/full length N-terminal His6-tagged MEP50 (unknown origin) expressed in baculovirus infec...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2021
Entry Details Article
PubMed
LigandPNGBDBM533482(US11220524, Example 87-B | (Z)-7-((1R,2S,3R,4S)-4-...)
Affinity DataIC50: 0.330nMAssay Description:Compounds were solubilized, and 3-fold diluted in 100% DMSO. These diluted compounds were further diluted in the assay buffer (50 mM Tris-HCl, pH 8.5...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/14/2022
Entry Details
US Patent

LigandPNGBDBM515323(US11098059, Example 27 | 6-(hexahydro-3,6- epimino...)
Affinity DataIC50: 0.350nMAssay Description:In this assay, the potency (IC50) of each compound was determined from a twenty-point (1:2 serial dilution; top compound concentration of 100000 nM) ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2022
Entry Details
US Patent

LigandPNGBDBM515309(US11098059, Example 13)
Affinity DataIC50: 0.360nMAssay Description:In this assay, the potency (IC50) of each compound was determined from a twenty-point (1:2 serial dilution; top compound concentration of 100000 nM) ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2022
Entry Details
US Patent

LigandPNGBDBM50523643(CHEMBL4454890)
Affinity DataIC50: 0.400nMAssay Description:Inhibition of full-length human N-terminal FLAG-tagged PRMT5/full length N-terminal His6-tagged MEP50 (unknown origin) expressed in baculovirus infec...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2021
Entry Details Article
PubMed
LigandPNGBDBM515306(US11098059, Example 10 | 6-(1-cyclopropyl-1H-1,2,4...)
Affinity DataIC50: 0.400nMAssay Description:In this assay, the potency (IC50) of each compound was determined from a twenty-point (1:2 serial dilution; top compound concentration of 100000 nM) ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2022
Entry Details
US Patent

LigandPNGBDBM533414(US11220524, Example 66 | 7-((2R,3R,4S,5R)-5-((R)-(...)
Affinity DataIC50: 0.400nMAssay Description:Compounds were solubilized, and 3-fold diluted in 100% DMSO. These diluted compounds were further diluted in the assay buffer (50 mM Tris-HCl, pH 8.5...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/14/2022
Entry Details
US Patent

LigandPNGBDBM515321(US11098059, Example 25 | 2-((R)-2-hydroxy-2-((S)- ...)
Affinity DataIC50: 0.440nMAssay Description:In this assay, the potency (IC50) of each compound was determined from a twenty-point (1:2 serial dilution; top compound concentration of 100000 nM) ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2022
Entry Details
US Patent

LigandPNGBDBM515305(US11098059, Example 9 | 6-(1-cyclopropyl-1H-1,2,4-...)
Affinity DataIC50: 0.470nMAssay Description:In this assay, the potency (IC50) of each compound was determined from a twenty-point (1:2 serial dilution; top compound concentration of 100000 nM) ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2022
Entry Details
US Patent

LigandPNGBDBM515319(US11098059, Example 23)
Affinity DataIC50: 0.5nMAssay Description:In this assay, the potency (IC50) of each compound was determined from a twenty-point (1:2 serial dilution; top compound concentration of 100000 nM) ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2022
Entry Details
US Patent

LigandPNGBDBM578831(US11492351, Example 4-107 | 2-(4-(4-(aminomethyl)-...)
Affinity DataIC50: 0.5nMAssay Description:The assay uses purified human, PRMT5 enzyme to convert S-adenosyl-L-[methyl-3H]methionine plus histone H4 L-arginine to S-adenosyl-L-homocysteine plu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2022
Entry Details
US Patent

LigandPNGBDBM578895(US11492351, Example 4-78 | 4-(aminomethyl)-6-(5-(2...)
Affinity DataIC50: 0.5nMAssay Description:The assay uses purified human, PRMT5 enzyme to convert S-adenosyl-L-[methyl-3H]methionine plus histone H4 L-arginine to S-adenosyl-L-homocysteine plu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2022
Entry Details
US Patent

LigandPNGBDBM578819(US11492351, Example 4-100 | US11479551, Example 4-...)
Affinity DataIC50: 0.5nMAssay Description:The assay uses purified human, PRMT5 enzyme to convert S-adenosyl-L-[methyl-3H]methionine plus histone H4 L-arginine to S-adenosyl-L-homocysteine plu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/20/2023
Entry Details
US Patent

LigandPNGBDBM435525(US10570140, Example 12 | (2R,3S,4R,5R)-2-(((2-amin...)
Affinity DataIC50: 0.5nMAssay Description:Compounds were solubilized and 3-fold diluted in 100% DMSO. These diluted compounds were further diluted in the assay buffer (50 mM Tris-HCl, pH 8.5,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/30/2020
Entry Details
US Patent

LigandPNGBDBM578821(US11492351, Example 4-101 | 2-(4-(4-(aminomethyl)-...)
Affinity DataIC50: 0.5nMAssay Description:The assay uses purified human, PRMT5 enzyme to convert S-adenosyl-L-[methyl-3H]methionine plus histone H4 L-arginine to S-adenosyl-L-homocysteine plu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/20/2023
Entry Details
US Patent

LigandPNGBDBM578819(US11492351, Example 4-100 | US11479551, Example 4-...)
Affinity DataIC50: 0.5nMAssay Description:The assay uses purified human, PRMT5 enzyme to convert S-adenosyl-L-[methyl-3H]methionine plus histone H4 L-arginine to S-adenosyl-L-homocysteine plu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2022
Entry Details
US Patent

LigandPNGBDBM578823(US11492351, Example 4-103 | 2-(4-(4-(aminomethyl)-...)
Affinity DataIC50: 0.5nMAssay Description:The assay uses purified human, PRMT5 enzyme to convert S-adenosyl-L-[methyl-3H]methionine plus histone H4 L-arginine to S-adenosyl-L-homocysteine plu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/20/2023
Entry Details
US Patent

LigandPNGBDBM435525(US10570140, Example 12 | (2R,3S,4R,5R)-2-(((2-amin...)
Affinity DataIC50: 0.5nMAssay Description:Compounds were solubilized and 3-fold diluted in 100% DMSO. These diluted compounds were further diluted in the assay buffer (50 mM Tris-HCl, pH 8.5,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2022
Entry Details
US Patent

LigandPNGBDBM578821(US11492351, Example 4-101 | 2-(4-(4-(aminomethyl)-...)
Affinity DataIC50: 0.5nMAssay Description:The assay uses purified human, PRMT5 enzyme to convert S-adenosyl-L-[methyl-3H]methionine plus histone H4 L-arginine to S-adenosyl-L-homocysteine plu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2022
Entry Details
US Patent

LigandPNGBDBM578825(US11492351, Example 4-104 | 2-(4-(4-(aminomethyl)-...)
Affinity DataIC50: 0.5nMAssay Description:The assay uses purified human, PRMT5 enzyme to convert S-adenosyl-L-[methyl-3H]methionine plus histone H4 L-arginine to S-adenosyl-L-homocysteine plu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/20/2023
Entry Details
US Patent

LigandPNGBDBM578823(US11492351, Example 4-103 | 2-(4-(4-(aminomethyl)-...)
Affinity DataIC50: 0.5nMAssay Description:The assay uses purified human, PRMT5 enzyme to convert S-adenosyl-L-[methyl-3H]methionine plus histone H4 L-arginine to S-adenosyl-L-homocysteine plu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2022
Entry Details
US Patent

LigandPNGBDBM578825(US11492351, Example 4-104 | 2-(4-(4-(aminomethyl)-...)
Affinity DataIC50: 0.5nMAssay Description:The assay uses purified human, PRMT5 enzyme to convert S-adenosyl-L-[methyl-3H]methionine plus histone H4 L-arginine to S-adenosyl-L-homocysteine plu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2022
Entry Details
US Patent

LigandPNGBDBM578829(US11492351, Example 4-106 | 2-(4-(4-(aminomethyl)-...)
Affinity DataIC50: 0.5nMAssay Description:The assay uses purified human, PRMT5 enzyme to convert S-adenosyl-L-[methyl-3H]methionine plus histone H4 L-arginine to S-adenosyl-L-homocysteine plu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/20/2023
Entry Details
US Patent

LigandPNGBDBM578831(US11492351, Example 4-107 | 2-(4-(4-(aminomethyl)-...)
Affinity DataIC50: 0.5nMAssay Description:The assay uses purified human, PRMT5 enzyme to convert S-adenosyl-L-[methyl-3H]methionine plus histone H4 L-arginine to S-adenosyl-L-homocysteine plu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/20/2023
Entry Details
US Patent

LigandPNGBDBM578895(US11492351, Example 4-78 | 4-(aminomethyl)-6-(5-(2...)
Affinity DataIC50: 0.5nMAssay Description:The assay uses purified human, PRMT5 enzyme to convert S-adenosyl-L-[methyl-3H]methionine plus histone H4 L-arginine to S-adenosyl-L-homocysteine plu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/20/2023
Entry Details
US Patent

LigandPNGBDBM578829(US11492351, Example 4-106 | 2-(4-(4-(aminomethyl)-...)
Affinity DataIC50: 0.5nMAssay Description:The assay uses purified human, PRMT5 enzyme to convert S-adenosyl-L-[methyl-3H]methionine plus histone H4 L-arginine to S-adenosyl-L-homocysteine plu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2022
Entry Details
US Patent

LigandPNGBDBM515317(US11098059, Example 21)
Affinity DataIC50: 0.520nMAssay Description:In this assay, the potency (IC50) of each compound was determined from a twenty-point (1:2 serial dilution; top compound concentration of 100000 nM) ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2022
Entry Details
US Patent

LigandPNGBDBM515315(US11098059, Example 19)
Affinity DataIC50: 0.530nMAssay Description:In this assay, the potency (IC50) of each compound was determined from a twenty-point (1:2 serial dilution; top compound concentration of 100000 nM) ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2022
Entry Details
US Patent

LigandPNGBDBM533402(US11220524, Example 20 | (2R,3S,4R,5R)-2-((R)-(4- ...)
Affinity DataIC50: 0.600nMAssay Description:Compounds were solubilized, and 3-fold diluted in 100% DMSO. These diluted compounds were further diluted in the assay buffer (50 mM Tris-HCl, pH 8.5...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/14/2022
Entry Details
US Patent

LigandPNGBDBM578885(US11492351, Example 4-73 | 4-(aminomethyl)-6-(5-(2...)
Affinity DataIC50: 0.600nMAssay Description:The assay uses purified human, PRMT5 enzyme to convert S-adenosyl-L-[methyl-3H]methionine plus histone H4 L-arginine to S-adenosyl-L-homocysteine plu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/20/2023
Entry Details
US Patent

LigandPNGBDBM578922(US11492351, Example 4-46 | 4-(aminomethyl)-6-(3-(m...)
Affinity DataIC50: 0.600nMAssay Description:The assay uses purified human, PRMT5 enzyme to convert S-adenosyl-L-[methyl-3H]methionine plus histone H4 L-arginine to S-adenosyl-L-homocysteine plu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2022
Entry Details
US Patent

LigandPNGBDBM578922(US11492351, Example 4-46 | 4-(aminomethyl)-6-(3-(m...)
Affinity DataIC50: 0.600nMAssay Description:The assay uses purified human, PRMT5 enzyme to convert S-adenosyl-L-[methyl-3H]methionine plus histone H4 L-arginine to S-adenosyl-L-homocysteine plu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/20/2023
Entry Details
US Patent

LigandPNGBDBM578885(US11492351, Example 4-73 | 4-(aminomethyl)-6-(5-(2...)
Affinity DataIC50: 0.600nMAssay Description:The assay uses purified human, PRMT5 enzyme to convert S-adenosyl-L-[methyl-3H]methionine plus histone H4 L-arginine to S-adenosyl-L-homocysteine plu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2022
Entry Details
US Patent

LigandPNGBDBM533415(US11220524, Example 67 | 7-((2R,3R,4S,5R)-5-((R)-(...)
Affinity DataIC50: 0.600nMAssay Description:Compounds were solubilized, and 3-fold diluted in 100% DMSO. These diluted compounds were further diluted in the assay buffer (50 mM Tris-HCl, pH 8.5...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/14/2022
Entry Details
US Patent

LigandPNGBDBM50523663(CHEMBL4536042)
Affinity DataIC50: 0.600nMAssay Description:Inhibition of PRMT5 (unknown origin)/MEP50 (unknown origin) using histone H2 as substrate preincubated for 15 to 20 mins followed by S-[methyl-3H]ade...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2021
Entry Details Article
PubMed
LigandPNGBDBM515313(US11098059, Example 17)
Affinity DataIC50: 0.610nMAssay Description:In this assay, the potency (IC50) of each compound was determined from a twenty-point (1:2 serial dilution; top compound concentration of 100000 nM) ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2022
Entry Details
US Patent

LigandPNGBDBM515308(US11098059, Example 12 | 4-ethyl-2-{2-hydroxy-2-[(...)
Affinity DataIC50: 0.630nMAssay Description:In this assay, the potency (IC50) of each compound was determined from a twenty-point (1:2 serial dilution; top compound concentration of 100000 nM) ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2022
Entry Details
US Patent

LigandPNGBDBM533478(US11220524, Example 85-B | (Z)-7-((1R,2S,3R,4S)-4-...)
Affinity DataIC50: 0.640nMAssay Description:Compounds were solubilized, and 3-fold diluted in 100% DMSO. These diluted compounds were further diluted in the assay buffer (50 mM Tris-HCl, pH 8.5...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/14/2022
Entry Details
US Patent

LigandPNGBDBM584223((2R,3R,4S,5R)-2-(4-amino-5-fluoro- 7H-pyrrolo[2,3-...)
Affinity DataIC50: 0.700nMAssay Description:HotSpot Assay. Compounds were solubilized and 3-fold diluted in 100% DMSO. These diluted compounds were further diluted in the assay buffer (50 mM Tr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2023
Entry Details
US Patent

Displayed 1 to 50 (of 3475 total ) | Next | Last >>
Jump to: